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SUMMARY Tissue kallikrein is an enzyme that forms the vasoactive peptide kallidin from an
endogenous substrate L-kininogen. Tissue kallikrein has been identified in joint fluids and in
inflammatory infiltrates within synovial membranes. It is suggested that tissue kallikrein and
kinins have an important role in synovitis and joint damage. Immunoreactive tissue kallikrein
and amidase activity were both measured in the synovial fluid of 24 patients with rheumatoid
arthritis (RA) and 12 with osteoarthritis (OA). Active enzyme concentrations were higher in RA
than in OA and correlated well with the lysosomal enzymes ,-glucuronidase and lactate
dehydrogenase. Both total immunoreactive tissue kallikrein and the proenzyme values were
similar in RA and OA. Tissue kallikrein was localised by immunocytochemistry to
the polymorphonuclear leucocytes present in the synovial fluid and membranes of patients with
RA.
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Tissue kallikreins are a family of closely related
serine proteases of physiological importance. Their
tissue specific functions are largely unknown, but
they are known to produce the inflammatory
mediator kallidin (lysyl-bradykinin).t Kallidin be-
longs to the group of vasoactive peptides known as
kinins. Many of the effects of kinins, including
vasodilatation, increased vascular permeability,
leucotaxis, and pain, occur in inflammatory joint
disease.2 When bradykinin was injected into the
knees of dogs it produced acute heat, pain, and
effusion.3 Furthermore, both bradykinin4 and
kallidin5 have recently been put forward as possible
mediators of bone resorption. In 1957 Armstrong et
al first described a pain producing substance similar
to bradykinin in the synovial fluid of patients with
rheumatoid arthritis (RA).6 Although bradykinin
had been reported in fluid from inflamed3 and
gouty7 joints, it was only later shown to be present
in greater amounts than in osteoarthritic (OA)
joints.
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Plasma kallikrein, the serine protease that forms
bradykinin, is a component of the intrinsic blood
coagulation cascade and was first implicated in gout
by Kellermeyer and Breckenridge.9 Subsequently,
plasma kallikrein was detected in RA synovial fluid
by Jasani et al,'0 and it has recently been shown that
significantly higher activity is present in RA than in
OA synovial fluid.'1 Unlike plasma kallikrein, tissue
kallikrein has hitherto not been positively identified
in joint fluid. The two enzymes differ in structure,
physicochemical and immunological properties, and
in their susceptibility to inhibitors. 12 13 Tissue kallik-
rein in cells and in biological fluids exists in one of
multiple forms: as an active enzyme, as a proenzyme
activated by limited proteolysis, and as an inactive
complex bound to selective protease inhibitors. Our
interest in the possible role of tissue kallikrein in
RA was prompted by the observation that increased
amounts of anionic tissue kallikreins occur in the
saliva of patients with connective tissue diseases,
including RA (Greaves, Whicher, Bhoola et al,
unpublished data). This finding led to a proposal
that such a change may occur in joint fluids. As a
first step it was necessary to identify tissue kallikrein
in synovial fluid and distinguish it from known
amidases like plasma kallikrein and elastase. 14
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In the present study we measured amidase,
immunoreactive tissue kallikrein, and kininogenase
concentrations in synovial fluid from the knee joints
of patients with RA. As normal synovial fluid was
unavailable patients with OA were used as a
comparative group. In addition, we investigated the
tissue site and possible source of immunoreactive
tissue kallikrein in the synovial fluid.
Patients and methods
PATIENTS
Twenty four patients (nine men and 15 women,
mean age 60-7 years, range 38-75 years) were
diagnosed as definite or classical RA according to
American Rheumatism Association criteria.'5 One
patient in this group had both knees aspirated, and
two patients each had the same knee aspirated on
two separate visits, making a total of 27 samples.
Twelve patients (two men and 10 women, mean age
70-8 years, range 55-90 years) had OA diagnosed by
standard clinical and x ray assessments and from the
analysis of synovial fluid. Two patients in this group
had both knees aspirated, making a total of 14
samples. One rheumatoid synovial fluid was used
for kininogenase measurement. For immuno-
cytochemistry synovial fluid pellets and biopsy
specimens of inflamed synovial membrane were
obtained from 15 patients with RA undergoing
therapeutic arthroscopy.
SAMPLE COLLECTION
Synovial fluid samples were collected in plain tubes.
Samples were spun at 12 500 g for five minutes at
4°C in a microcentrifuge (Burkard, Coolspin). The
pellets from 15 samples were fixed for immuno-
cytochemistry. The supematants were stored at
-70°C. Immediately before assay each sample was
treated with hyaluronidase (22.5 IU/ml supernatant)
for 30 minutes at 37°C.
ENZYME ACTIVITY
Amidase activity was measured using the selective
tissue kallikrein synthetic substrate H-D-Val-Leu-
Arg-pNA (S-2266, Kabi Diagnostica); enzymic
cleavage of the substrate produces p-nitroaniline
(pNA). 16 The reaction was carried out at 37°C and
pH 8-2 in the presence of soybean trypsin inhibitor
(cuvette concentration 125 tig/ml). The rate of
increase in absorption at 405 nm was followed on a
Unicam SP1800 spectrophotometer. The activity of
amidase resistant to soybean trypsin inhibitor was
expressed as tissue kallikrein equivalents in mU/ml,
where one unit (U) of tissue kallikrein hydrolyses
1 .tmol/itre substrate per minute. To measure the
proenzyme amidase activity the sample was acti-
vated with bovine trypsin (100 ig/ml) for 15 minutes
at 37°C. The reaction was stopped with soybean
trypsin inhibitor (100 ig/ml) and the tissue kallikrein
equivalent activity measured as before. 17 Activity of
the proenzyme (inactive) was determined by sub-
tracting the value for active from that obtained after
trypsinisation. The concentration of soybean trypsin
inhibitor (125 ,ug/ml) in the reaction mixture was
sufficient to inhibit the activity of plasma kallikrein
(14-5 ILg/ml) and elastase (3.75 ig/ml) on the
H-D-Val-Leu-Arg-pNA substrate. The amidases
resistant to soybean trypsin inhibitor (active and
proenzyme) were almost completely (90%-95%)
inhibited by aprotinin (5000 kIU/ml).
,-Glucuronidase activity was measured by the
method of Fishman with minor modifications. 18
Lactate dehydrogenase activity was measured col-
orimetrically with a Sigma diagnostic kit.
RADIOIMMUNOASSAY FOR TISSUE
KALLIKREIN
Tissue kallikrein was measured by radioimmuno-
assay by the method of Bagshaw et al. 19 The rabbit
antihuman urinary kallikrein antiserum, raised in
our laboratory, is known to have a high specificity
for human tissue kallikreins.19 Elastase showed no
cross reactivity with antihuman urinary kallikrein
either in the radioimmunoassay or in immunoblots
performed on cellulose nitrate paper.
PROTEIN
The protein content of the samples was measured by
the Coomassie blue dye binding method of
Bradford.20
KININOGENASE ASSAY
To measure the kininogenase activity of tissue
kallikrein in the synovial fluid it was first necessary
to deplete endogenous kininogen and inhibit plasma
kallikrein present in the synovial fluid. Freeze dried
synovial fluid, equivalent to 150 gIl of the original
sample, was reconstituted in 50 mM NaH2PO4 pH
7-4 and mixed with 100 RI of a freshly prepared
solution of bovine trypsin (22 gg) in the same buffer.
Firstly, the mixture was incubated for 15 minutes at
37°C to consume all endogenous kininogen. Next,
soybean trypsin inhibitor (150 gg in the same buffer)
was added to inhibit the bovine trypsin as well as the
plasma kallikrein; the incubation was continued for
10 minutes at 37°C and a further 10 minutes at room
temperature to permit degradation of kinin by
kininases known to be present in synovial fluid. This
reaction mixture was subsequently assayed for free
kinin and for kininogenase activity and its inhibition
by aprotinin, according to the methods described by
Fink et al.2'
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To measure free kinin the final incubate was
mixed with absolute ethanol (1 ml) and heated for
10 minutes to 70°C. After centrifugation the super-
natant was removed quantitatively, evaporated, and
the dried residue analysed for kinin.
To measure the kininogenase activity and its
inhibition by aprotinin two aliquots (50 RI) of the
final incubate were mixed, one with 100 mM
NaH2PO4, 3 mM 1,10-phenanthroline, 30 mM
edetic acid pH 8-5 and the other, in addition, with
aprotinin solution (5 tsg/ml in the same buffer).
After 10 minutes at room temperature (to allow
complex formation with aprotinin) kininogenase
activity was determined as described by Fink et al.21
In brief: the sample (50 ,ul) was incubated with dog
kininogen at 37°C for 30 minutes in the presence of
kininase inhibitors; next, ethanol was added to stop
the reaction and precipitate proteins. After centri-
fugation the supernatant (which contained the re-
leased kinin) was evaporated to dryness. The dried
residue was dissolved and the solution analysed for
the presence of kinin by radioimmunoassay.2' After
subtracting the value for free kinin (see above)
prokininogenase activity was calculated as fmoles
kinin released per minute by 1 ml of synovial fluid.
IMMUNOCYTOCHEMISTRY
Pellets from synovial fluid samples and synovial
membrane biopsy specimens were fixed in 4%
formal-saline for 12-18 hours and embedded in
paraffin wax. Serial sections from paraffin wax
embedded samples were immunostained according
to the peroxidase-antiperoxidase method.22 Before
incubation with antibodies to human tissue kallik-
rein (purified from either saliva or urine19) the
sections were treated with methanol and hydrogen
peroxide to block endogenous pseudoperoxidase
- 23activity. Controls included preabsorption of the
primary antiserum with purified human urinary
kallikrein (40 Rtg/ml) and omission of the primary
antiserum to confirm absence of residual
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pseudoperoxidase activity after treatment with
methanol and hydrogen peroxide. After staining
sections were counterstained with Giemsa or
haematoxylin.
STATISTICS
All results except kininogenase activity are ex-
pressed per mg protein in the synovial fluid. The
data were analysed using the two sided Mann-
Whitney U test and the Spearman rank correlation
coefficient.24
MATERIALS
All reagents used were of analytical reagent grade or
purer and, except where stated, were obtained from
Sigma Chemicals, Poole, Dorset.
Results
AMIDASE ACTIVITY AND
RADIOIMMUNOASSAY
Measurements were analysed in relation to patients
Table 1 Results ofmeasurements on patients with
rheumatoid arthritis (RA) and osteoarthritis (OA). Results
are presented as mean (SEM)
RA OA p Values
Active amidase
(mU/mg protein) 0-023 (0.003) 0-006 (0-002) 0-001
Inactive amidase
(mU/mg protein) 11-2 (0-5) 13-4 (1-1) 0.1
Immunoreactive
tissue kallikrein
(ng/mg protein) 0-155 (0-011) 0-205 (0-012) 0.01
f1-Glucuronidase(OD* units/mg
protein) 0-011 (0-001) 0-007 (0-001) 0-001
Lactic dehydro-
genase (units/mg
protein) 104-6 (9-3) 38-5 (5-1) 0-001
Protein (mg/ml) 40-5 (1-5) 33-3 (0.9) 0-002
*OD=optical density.
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Fig. 1 Distribution ofsoybean
trypsin inhibitor resistant amidase
levels reflecting active tissue
kallikrein, measured in synovial
fluidsfrom patients with
rheumatoid arthritis and
osteoarthritis.
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Fig. 2 Immunoreactive tissue kallikrein is visualised in polymorphonuclear leucocytes (arrows) present (a) in the
inflammatory infiltrate ofthe synovial membrane and (b) in the synovialfluid pellet. Only polymorphonuclear
leucocytes show immunostaining, whereas the synovial cells (SC), lymphocytes, and macrophages remain unstained.
(a) bar=15 Mm; (b) bar=25 ,im.
age, sex, and disease classification. None of the
factors measured varied with patients' age, and no
significant sex differences were found. Table 1 gives
the results from the RA and OA groups. Levels of
active amidase resistant to soybean trypsin inhibitor
(tissue kallikrein equivalent) (Fig. 1) were
significantly higher in RA than in OA (p<0-001).
Conversely, neither inactive amidase nor immuno-
reactive tissue kallikrein showed any significant
difference between the RA and OA groups; nor did
they correlate with one another or with any other
factor. In all patients most of the tissue kallikrein
equivalent enzymic activity seemed to be present in
the precursor form. In addition to the subjects with
RA we examined two female patients with psoriatic
arthritis and two male patients with monarthritis; all
four had levels of active amidase resistant to
soybean trypsin inhibitor above 0-015 mU/mg
protein. Conversely, in seven out of 14 patients with
OA and in one patient with RA in a quiescent phase
no such amidase activity was measurable in the joint
fluid.
The mean values for P-glucuronidase and lactic
dehydrogenase activities were significantly higher in
RA than in OA (p<0-001 in both cases). Total
protein concentration was also higher in RA
(p<0-002). A correlation of 0-67 was obtained
between P-glucuronidase and lactic dehydrogenase
activities. These parameters also correlated well
with active amidase resistant to soybean trypsin
inhibitor (0-66 for P-glucuronidase, 0-62 for lactic
dehydrogenase).
KININOGENASE ACTIVITY
The kinin released by trypsin activation of tissue
prokallikrein in synovial fluid was 491 fmol/min/ml.
This kininogenase activity was completely inhibited
by aprotinin but not by soybean trypsin inhibitor; an
inhibitor profile which strongly suggests that
kininogenase is a tissue kallikrein. Purified human
urinary kallikrein under these assay conditions
released 73 fmol/min/ng of kinin.2' The kini-
nogenase activity in synovial fluid corresponded to a
concentration of 6*7 ng/ml of tissue kallikrein as
measured by radioimmunoassay.
IMMUNOCYTOCHEMISTRY
Immunoreactive polymorphonuclear leucocytes
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were numerous in the pellets prepared from RA
synovial fluids; in some cases forming the major cell
type (Fig. 2). They were not as abundant in the
inflammatory infiltrate of synovial membranes (Fig.
2). At both sites polymorphonuclear leucocytes
were the only cell type that showed immunoreactive
human tissue kallikrein. Irrespective of their loca-
lisation in the fluid or in the inflamed synovial
membranes, polymorphonuclear leucocytes showed
a variable amount of immunoreactivity to tissue
kallikrein and displayed a granular staining similar
to that observed in polymorphonuclear leucocytesfrom normal blood. 5
Discussion
Our immunoreactive and kininogenase assays
clearly indicate the presence of a tissue kallikrein in
synovial fluid. Final confirmation of the precise
classification of this kallikrein must await purifica-
tion of the enzyme and elucidation of the chemical
structure of the kinin released. Such experiments
are in progress.
Although the activity of amidase resistant to
soybean trypsin inhibitor, representing tissue kalli-
krein, was present in every RA synovial fluid
examined, most seemed to be in an inactive form.
Urinary tissue prokallikrein is converted to active
tissue kallikrein by the loss of seven amino acids.26
A similar proenzyme may be present in synovial
fluid either alone or bound in a complex with a
selective inhibitor. Active tissue kallikrein is able to
form inactive complexes with selective protease
inhibitors.27 Hence trypsinisation may be activating
free or bound tissue prokallikrein or exposing the
active site of bound active tissue kallikrein. In either
case dissociation of the complex need not necess-
arily occur for detection of the enzyme. The major
tissue kallikrein inhibitor in human plasma, 28 29 also
abundant in synovial fluid,? 31 is probably func-
tionally important in regulating this enzyme in the
joint. The enzyme value attributed to inactive
amidase (see Table 1) may be due both to the
activity of trypsin bound to a2 macroglobulin and to
tissue kallikrein, converted from its proenzyme form
by trypsinisation. Amidase activity of the trypsin-a2
macroglobulin complex, like tissue kallikrein, is
resistant to soybean trypsin inhibitor.
An amidase resistant to soybean trypsin inhibitor
with kinin forming activity has previously been
described in synovial biopsy specimens taken from
rat, dog, and man by Al-Haboubi and colleagues.32
Our results demonstrate for the first time, however,
that polymorphonuclear leucocytes, present in large
numbers in the synovial fluid from patients with
RA, contain immunoreactive tissue kallikrein.
Furthermore, polymorphonuclear leucocytes pres-
ent in the inflammatory infiltrates of synovial
membrane biopsy specimens taken from the same
patients reacted with antibodies to tissue kallikrein.
Accumulation of polymorphonuclear leucocytes
at sites of inflammation is accompanied by an
increase in vascular permeability.33 Several types of
mediator affect permeability of blood vessels during
the early phases of inflammation.34 35 Kallidin,
produced by the action of tissue kallikrein on
L-kininogen, is considered to be one of the
mediators. It causes constriction of venules, increase
in vascular permeability, and pain. The presence of
immunoreactive tissue kallikrein in polymorphonu-
clear leucocytes suggests that this enzyme could
contribute to kinin formation during inflammatory
synovitis.
Recent reports suggest that bradykinin, kallidin,
and des-Arg9-bradykinin may contribute not only to
capillary dilatation, vascular permeability, and pain,
but also to bone destruction.4 5 Furthermore, tissue
kallikrein may act on substrates other than L-
kininogen. 12 Therefore, possible functions for tissue
kallikrein in joint disease could include roles in
collagen turnover and in the dynamic regulation of
bone forming cells. Tissue kallikrein and kallidin
can be added to the list of potential mediators of
synovitis and joint damage.
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